Bristol-Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative medicines that help patients overcome serious diseases. Headquartered in Princeton, New Jersey, the company focuses its efforts on addressing significant unmet medical needs worldwide.

The company's portfolio includes key products such as Eliquis (apixaban) for atrial fibrillation, Opdivo (nivolumab) and Yervoy (ipilimumab) for various cancers, Revlimid (lenalidomide) and Pomalyst/Imnovid (pomalidomide) for multiple myeloma, and Orencia (abatacept) for autoimmune diseases. Bristol Myers Squibb primarily operates within the market segments of oncology, hematology, immunology, and cardiovascular conditions, with a strong emphasis on research and development.

Chris Boerner serves as the Board Chair and Chief Executive Officer, having assumed the role in November 2023. In the first quarter of 2026, Bristol Myers Squibb reported revenues of $11.5 billion, marking a 3% increase from the same period in 2025. The company continues to navigate patent expiration risks by expanding indications for existing therapies and advancing a robust pipeline of late-stage assets, while also positioning new treatments like Cobenfy for conditions such as Alzheimer's psychosis.

Latest updates

Bristol Myers Squibb Ties 'Won’t Lose' Campaign to FIFA World Cup 2026

Event summary

  • Bristol Myers Squibb launched the 'Won’t Lose' campaign ahead of the FIFA World Cup 2026.
  • The campaign features narration from Ali Krieger, a two-time FIFA Women’s World Cup Champion.
  • Assets will be integrated across CTV, programmatic display, audio, video, and social media.
  • The campaign underscores BMS’s commitment to advancing breakthrough medicines for patients.

The big picture

Bristol Myers Squibb’s 'Won’t Lose' campaign leverages the FIFA World Cup 2026 to reinforce its mission-driven narrative. The move aligns with broader industry trends where pharmaceutical companies use high-profile cultural events to enhance brand visibility and patient engagement. The campaign’s success will hinge on its ability to translate emotional resonance into tangible trust and loyalty among key stakeholders.

What we're watching

Brand Impact
How the campaign will affect BMS’s brand perception among patients and investors.
Campaign Effectiveness
Whether the campaign can sustain engagement and drive patient awareness.
Strategic Alignment
The pace at which BMS integrates cultural moments into its long-term strategy.

BMY Reports Q1 2026, Conference Call Scheduled

Event summary

  • Bristol Myers Squibb released its first quarter 2026 financial results on April 30, 2026.
  • Detailed results and an investor presentation are available on the company's Investor Relations website.
  • A conference call and live audio webcast for analysts and investors is scheduled for 8:00 a.m. ET today.
  • A replay of the webcast will be available approximately three hours after the call concludes.

The big picture

The release signals the start of the Q1 2026 earnings cycle for major pharmaceutical players. Bristol Myers Squibb's performance will be a key indicator of the sector's resilience amid ongoing inflation and potential shifts in healthcare policy. The conference call will provide crucial insights into the company's strategic priorities and outlook for the remainder of the year.

What we're watching

Financial Scrutiny
Investor attention will be focused on the specific revenue figures and margins disclosed, given the broader macroeconomic uncertainty impacting healthcare spending.
Pipeline Progress
The conference call will likely reveal updates on key clinical trial milestones and regulatory submissions, which will significantly influence future growth expectations.
Market Dynamics
The company's commentary on competitive pressures and pricing dynamics within the oncology and immunology spaces will be critical to assessing its long-term market position.

Eliquis Joins Cost Plus Drugs, Challenging Pharma Pricing

Event summary

  • Bristol Myers Squibb and Pfizer are offering Eliquis (apixaban) on Mark Cuban Cost Plus Drug Company's platform, starting April 27, 2026.
  • The 30-day supply price will be $345, significantly lower than typical retail prices.
  • This collaboration marks a major brand – Eliquis is one of the largest in its category – joining the Cost Plus Drugs platform.
  • The move follows BMS-Pfizer’s 2025 launch of a direct-to-patient offering through Eliquis 360 Support.

The big picture

This collaboration represents a significant challenge to the traditional pharmaceutical distribution model, bypassing pharmacy benefit managers (PBMs) and offering patients a more transparent price. The move by BMS-Pfizer, a combined entity with substantial revenue, signals a willingness to experiment with alternative distribution channels in response to mounting pressure for drug price reform. Cost Plus Drugs' model, championed by Mark Cuban, has gained traction by appealing to consumers frustrated with opaque pricing and high out-of-pocket costs, and Eliquis' inclusion validates the platform's potential to disrupt the market.

What we're watching

Market Adoption
The volume of Eliquis prescriptions fulfilled through Cost Plus Drugs will indicate the level of patient demand for this pricing model and its potential impact on BMS-Pfizer’s overall sales.
Competitive Response
Other pharmaceutical companies will likely observe this move closely, and the success or failure of this collaboration could influence their own direct-to-consumer strategies.
Regulatory Scrutiny
The initiative may draw attention from regulators concerned with drug pricing and transparency, potentially leading to increased oversight of direct-to-consumer pharmaceutical sales.
CID: 3497